Tekla Life Sciences Investors

Find Ratings Reports
HQL : NYSE : Financial
$20.98 up 0.08 | 0.38%
Today's Range: 20.84 - 21.0
Avg. Daily Volume: 71500.0
05/26/17 - 3:57 PM ET

PEER GROUP ANALYSIS

HQL Peer Plot Chart

This chart compares HQL to the highest rated funds in its peer group of Sector - Health/Biotechnology funds. The above graph illustrates two key measures that investors should consider when assessing the investment potential of a particular fund. One of the key factors is how the fund has performed over the most recent reporting period, defined as the 1 year total return on the bottom axis. The second factor is the fund's reported expense ratio, on the right axis, which includes things like management fees. The best funds, with higher returns and lower expenses, stake out a position in the lower left part of this graph.


TOP RATED FUNDS : Sector - Health/Biotechnology
NameTickerReturn
YTD
1 Year
Return
3 Year
Return
Expense
Ratio
Peer
Rank
iShares US Healthcare Providers ETF IHF 9.75 9.12 13.42 0.44 1
iShares US Medical Devices ETF IHI 18.57 23.42 19.46 0.44 2
Fidelity MSCI Health Care Index ETF FHLC 10.85 11.79 11.59 0.12 3
iShares US Healthcare ETF IYH 10.35 11.04 11.06 0.44 4
Health Care Select Sector SPDR XLV 9.92 9.93 11.15 0.14 5
ETFis BioShares Biotech Products BBP 16.15 47.09 0.00 0.85 6
ETFis BioShares Biotech Clinical Tr BBC 22.92 14.47 0.00 0.85 7
Engex EGX 33.11 83.91 18.56 2.44 8
Vanguard HealthCare Index ETF VHT 10.89 11.89 11.63 0.10 9
Tekla Life Sciences Investors HQL 22.90 21.79 9.47 1.27 17
The above table compares the total return performance and expense ratio of Tekla Life Sciences Investors to the top rated funds within the Sector - Health/Biotechnology peer group. Tekla Life Sciences Investors ranks number 17 out of 35 Sector - Health/Biotechnology closed-end and exchange-traded funds that we rate.

Latest Stock Upgrades/Downgrades